interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Ziftomenib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Ziftomenib, and who makes it?

Ziftomenib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Ziftomenib1 dosage-form group in the Orange Book
0generic makers listed
  1. Ziftomenib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Komzifti. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 10174041 listed to expire 16 March 2036Patent 10077271 listed to expire 16 March 2036Patent 10869868 listed to expire 26 January 2037Patent 11673898 listed to expire 15 March 2037Patent 10781218 listed to expire 15 March 2037Patent 11944627 listed to expire 6 September 2038Patent 12410184 listed to expire 16 July 2044Patent 12521396 listed to expire 16 July 2044Exclusivity NCE to 13 November 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 13 November 2030Exclusivity NCE Komzifti
  • 16 March 2036Patent 10174041
  • 16 March 2036Patent 10077271 drug substance
  • 26 January 2037Patent 10869868
  • 15 March 2037Patent 11673898
  • 15 March 2037Patent 10781218 drug substance
  • 6 September 2038Patent 11944627
  • 16 July 2044Patent 12410184 drug substance
  • 16 July 2044Patent 12521396 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.